Highest-materiality recent filing
LifeMD Q2 revenue $47.3M, adjusted EBITDA loss $3.5M; revises FY2026 guidance
Revenue $47.3M within guidance; adjusted EBITDA loss $3.5M improved 21% sequentially but below guided range.
LifeMD will be the exclusive telehealth co-marketing partner for XYOSTED (testosterone enanthate) self-pay program.
LifeMD Q1 revenue $50.2M beats guidance; adds 42k subscribers, record GLP-1 signups
Revenue $50.2M vs guidance $48-49M; adj. EBITDA loss $4.5M in line.
LifeMD appoints new CFO, promotes CBO and CMO; outgoing CFO to advise
CFO Marc Benathen resigns effective March 31, 2026; will provide advisory services for 6–12 months at $38,117/month.
LifeMD FY2025 rev $194.1M (+25%), adj EBITDA $15.3M (+309%); guides to >$250M run-rate by Q4 2026
FY2025 revenue $194.1M (+25% YoY); adjusted EBITDA $15.3M (+309% YoY).
LifeMD closes $50M revolving credit facility with Citizens Bank, N.A.
Facility provides $30M committed plus $20M accordion; maturity January 2, 2029.
LifeMD Q3 revenue $60.2M (+13%), adj EBITDA $5.1M; paid off debt, sold WorkSimpli
Total revenue $60.2M (+13% YoY); adjusted EBITDA $5.1M (+20% YoY).
LifeMD delays Q3 earnings, expects late 10-Q filing due to $4.6M revenue recognition corrections
Q3 2025 earnings rescheduled to Nov 17, 2025; expects to file Form 12b-25 for late 10-Q.
LifeMD sells majority stake in WorkSimpli for $65M enterprise value; receives $22M cash at close
Sold 80% of WorkSimpli units to buyer group led by founder/CEO; enterprise value ~$65M.
LifeMD dismisses CBIZ CPAs, appoints PwC; cites material weaknesses in internal controls
On Aug 15, 2025, LifeMD dismissed CBIZ CPAs (appointed Apr 24, 2025) as auditor; no disagreements.
LifeMD Q2 revenue up 23% to $62.2M, adjusted EBITDA up 223% to $7.1M; revises FY2025 guidance
Total revenue $62.2M (+23% YoY), telehealth revenue $48.6M (+30%); telehealth adjusted EBITDA $3.4M (+560%).
LifeMD Q1 revenue up 49% to $65.7M; first GAAP profit; raises FY 2025 guidance
Total revenue $65.7M (+49% YoY); telehealth revenue up 70% to $55.8M.
LifeMD acquires Optimal Human Health MD assets for 100k shares; launches women's health vertical
Acquired key assets from Optimal Human Health MD for 100,000 shares of common stock (50k at close, 50k at 1yr) plus earn-out.
LifeMD Q4 revenue $64.3M (+43% YoY), adj EBITDA $9.0M; FY2025 rev guidance $265-275M
Q4 2024 revenue $64.3M (+43% YoY); telehealth revenue $49.9M (+60%); GAAP net loss narrowed to $0.9M from $4.5M.
LifeMD partners with Medifast, secures $20M investment for weight management collaboration
Medifast invests $20M total: $10M platform support payment and $10M purchase of 1,224,425 LifeMD shares at $8.1671/share.
LifeMD reports FY2021 preliminary revenue of $92.9M, +149% YoY; FY2022 guidance $142-148M
Preliminary Q4 2021 revenue $27.4M; FY2021 revenue $92.9M (149% YoY growth).
LifeMD acquires allergy telehealth platform Cleared; total consideration up to $76.7M
Upfront $460k cash + $3.46M milestone payments + up to $72.8M earn-out based on $150M revenue.
LifeMD raises $21.4M from common, $32.9M from preferred stock offerings
3.83M common shares sold at $6.00/share; net proceeds ~$21.4M; $5M used to repay debt.
Effective October 25, 2024, Naveen Bhatia voluntarily resigned from his position as a member of the board of directors (the “Board”) of LifeMD, Inc. (the “Company”).
On April 26, 2024, Calum MacRae was appointed to the Board of Directors.
Effective November 8, 2023, Bertrand Velge voluntarily resigned from his position as a member of the board of directors (the “Board”) of LifeMD, Inc. (the “Company”).
On July 28, 2023, Alex Mironov voluntarily resigned from his position as President of LifeMD, Inc. (the “Company”) in connection with his appointment as a Managing Director of Rothschild & Co.
On June 20, 2023, Stefan Galluppi resigned from the Board of Directors of LifeMD, Inc. (the "Company") effective immediately.
On June 20, 2023, William J. Febbo was appointed to the Board of Directors.
On February 9, 2023, LifeMD, Inc. (the “Company”) appointed Dr. Joan LaRovere to the board of directors (the “Board”) of the Company.
Effective February 9, 2023, Kathleen E. Walsh voluntarily resigned from her position as a member of the Board in connection with her appointment as the Secretary of the Executive Office of Health and Human Services for the Commonwealth of Massachusetts.
On December 15, 2022, LifeMD, Inc. (the “Company”) appointed Kathleen E. Walsh to the board of directors (the “Board”) of the Company.
On September 14, 2022, LifeMD, Inc. (the “Company”) appointed Robert Jindal to the board of directors (the “Board”) of the Company.
Effective February 4, 2022, Maria Stan was appointed as Controller and Principal Accounting Officer of LifeMD, Inc. (the “Company”).
Director Resignation Effective November 8, 2021, Dr. Eleanor C. Mariano voluntarily resigned from her position as a member of the board of directors (the “Board”) of LifeMD, Inc. (the “Company”).
Max materiality 0.80 · Median 0.50 · Most common event other_material